Nexalin Taps Neuromodulation Veteran to Drive Global Commercial Push
Event summary
- Nexalin appoints Robert DiTota, a 20-year neuromodulation veteran from Abbott and Medtronic, as Senior Strategic Advisor for Global Commercialization.
- DiTota previously led a $700M neuromodulation business at Abbott and grew revenue by $20M in his first year at Medtronic.
- Nexalin’s Gen-2 SYNC device is already approved in China, Brazil, Oman, and Israel, with plans to expand into the U.S. and Europe.
- The company aims to convert regulatory approvals into commercial sales, targeting a $7B neuromodulation market projected to reach $13.9B by 2033.
The big picture
Nexalin’s shift from clinical development to commercialization marks a critical phase for the company, leveraging its regulatory approvals and clinical data to enter a rapidly growing neuromodulation market. The appointment of DiTota signals a strategic move to build a robust commercial infrastructure, essential for competing against industry giants like Abbott and Medtronic. The success of this transition will hinge on Nexalin’s ability to convert its existing approvals into revenue and expand its market reach.
What we're watching
- Commercialization Execution
- Whether Nexalin can successfully translate its clinical and regulatory foundation into commercial sales, particularly in new markets.
- Market Penetration
- The pace at which Nexalin can establish distribution relationships and go-to-market plans in the U.S. and Europe.
- Competitive Positioning
- How Nexalin’s non-invasive DIFS™ platform will differentiate itself against established players like Abbott and Medtronic.